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Abstract
Context: Caveolins are 21-24 kDa integral membrane proteins that serve as scaffolds to recruit numerous signaling 
molecules. Specific subclasses of caveolae carry out specific functions in cell metabolism. In particular, triglycerides are 
synthesized at the site of fatty acid entry in one of these caveolae classes.
Objective and Methods: We studied the expression of caveolin-1 (CAV-1) gene in association with metabolic variables 
in 90 visceral and 55 subcutaneous adipose tissue samples from subjects with a wide range of fat mass, in the 
stromovascular fraction (SVC) and isolated adipocytes, and during differentiation of human adipocytes.
Results: CAV-1 gene expression was significantly decreased in visceral adipose tissue (v-CAV-1) of obese subjects. v-
CAV-1 was positively associated with several lipogenic genes such as acetyl-coA carboxylase (ACACA, r = 0.34, p = 0.004) 
and spot-14 (r = 0.33, p = 0.004). In non-obese subjects v-CAV-1 also correlated with fatty acid synthase (FAS, r = 0.60, p 
< 0.0001). Subcutaneous (sc) adipose tissue (sc-CAV-1) gene expression was not associated with these lipogenic factors 
when obese and non-obese subjects were studied together. In obese subjects, however, sc-CAV-1 was associated with 
fatty acid synthase (FAS, r = 0.36, p = 0.02), sterol regulatory element binding protein-1c (SREBP-1c (r = 0.58, p < 0.0001), 
ACACA (r = 0.33, p = 0.03), spot-14 (r = 0.36, p = 0.02), PPAR-γ co-activator-1 (PGC-1, r = 0.88, n = 19). In these obese 
subjects, sc-CAV-1 was also associated with fasting triglycerides (r = -0.50, p < 0.0001).
CAV-1 expression in mature adipocytes was significantly higher than in stromal vascular cells. CAV-1 gene expression
in adipocytes from subcutaneous adipose tissue (but not in adipocytes from visceral adipose tissue) was
significatively associated with fasting triglycerides. CAV-1  gene expression did not change significantly during
differentiation of human preadipocytes from lean or obese subjects despite significant increase of FAS gene
expression.
Conclusion: Decreased CAV-1 gene expression was simultaneously linked to increased triglycerides and decreased 
lipogenic gene expression among obese subjects, paralleling the observations of hypertriglyceridemia in CAV-1 
knockout mice. However, the regulation of CAV-1 gene expression seems independent of the adipogenic program.
Background
Obesity is an epidemic health problem worldwide that
impacts the risk and prognosis of many diseases, including
type 2 diabetes mellitus (DM-2), cardiovascular disease,
hyperlipidemia, and cancer [1]. Adipose tissue plays a criti-
cal role in energy homeostasis in higher organisms. It
serves as the main site for energy storage in the form of
triglycerides and also contributes to systemic glucose and
lipid metabolism via its function as an endocrine organ.
Lipid rafts are lateral assemblies of sphingolipids and
cholesterol that function as platforms to which distinct
classes of proteins are associated. Caveolae are a special-
ized type of lipid raft that appear in the plasma membrane
as 50-100-nm flask-shaped invaginations that project into
the cytosol. Caveolae are present in most cell types but are
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particularly abundant in adipocytes, where they account for
30% of the plasma membrane surface area [2]. In adipo-
cytes, CAV-1 isoform is responsible for caveolae formation
[3]. Caveolins are 21-24 kDa integral membrane proteins
that serve as scaffolds to recruit numerous signaling mole-
cules. Caveolae function has been implicated in membrane
traffic, signal transduction, substrate transport and endocy-
tosis [4]. In recent years, an in-depth knowledge of these
functions is increasingly recognized. Specific subclasses of
caveolae carry out specific functions in cell metabolism. In
particular, triglycerides are synthesized at the site of fatty
acid entry in one of these caveolae classes [5].
Fatty acid synthesis is of vital importance in cell physiol-
ogy in general, and in adipose tissue physiology in particu-
lar. The biosynthesis of the fatty acids (lipogenesis)
depends on well known enzyme-regulated processes. Stud-
ies in humans fed with a high carbohydrate diet demon-
strated that total body fat synthesis significantly exceeded
hepatic de novo lipogenesis, suggesting that adipose tissue
may be the major site for fat synthesis, with the adipose tis-
sue accounting for >40% of whole-body lipogenesis [6,7].
Several lines of evidence suggest interplay between CAV-
1 and fatty acid metabolism. CAV-1 null mice had a lean
phenotype and their adipocytes lack caveolae, a derange-
ment that translates into a systemic inability for lipid accu-
mulation with increasing age [8]. CAV-1-/-  mice were
hypertriglyceridemic. The impaired triglyceride clearance
took place in the setting of normal total and hepatic lipopro-
tein lipase activity, and reduced hepatic very low-density
lipoprotein (VLDL) secretion [9].
Additionally, CAV-1  deficiency was associated with an
increase in high-density lipoprotein (HDL). CAV-1  defi-
ciency prevented the transcytosis of LDL across endothelial
cells, and therefore, CAV-1 might be implicated in the regu-
lation of plasma LDL levels [9]. These metabolic altera-
tions were not accompanied by noticeable changes in
circulating glucose or insulin [8]. In humans, CAV-1 is one
of the locis identified associated with inherited lipodystro-
phy and hypertriglyceridemia [10]. In addition, the gene
encoding CAV-1 has been proposed as a quantitative trait
locus of triglyceridemia [11].
We aimed to evaluate the interrelationships among the
adipose tissue expressions of CAV-1, lipogenic genes and
circulating triglycerides in a cohort of obese and non-obese
subjects.
Methods
Subjects
Ninety adipose tissue samples were obtained from visceral
depots during elective surgical procedures (cholecystec-
tomy, surgery of abdominal hernia and gastric by-pass sur-
gery), washed, fragmented and immediately flash-frozen in
liquid nitrogen before be stored at -80°C. These at samples
were provided from a group of 90 subjects (31 men and 59
women) with a body mass index (BMI) between 21.5 and
70.0 kg/m2 who were invited to participate at the Endocri-
nology Service of the Hospital Universitari de Girona Dr.
Josep Trueta (Girona, Spain). Subcutaneous adipose tissue
was also obtained from 55 of these subjects, whose charac-
teristics did not differ significantly from the remaining sub-
jects. Fewer subjects were utilized for gene expression in
the subcutaneous depot because of tissue availability. All
subjects were of Caucasian origin and reported that their
body weight had been stable for at least three months before
the study. They had no systemic disease other than type 2
diabetes and obesity and all were free of any infections in
the previous month before the study. Liver disease and thy-
roid dysfunction were specifically excluded by biochemical
work-up. Other exclusion criteria for those patients
included the following: 1) clinically significant hepatic,
neurological, or other major systemic disease, including
malignancy; 2) history of drug or alcohol abuse, defined as
>80 g/day, or serum transaminase activity more than twice
the upper limit of normal; 3) an elevated serum creatinine
concentration; 4) acute major cardiovascular event in the
previous 6 months; 5) acute illnesses and current evidence
of high grade chronic inflammatory or infective diseases;
and  6) mental illness rendering the subjects unable to
understand the nature, scope, and possible consequences of
the study. All subjects gave written informed consent after
the purpose of the study was explained to them. The institu-
tional review board of each institution approved the proto-
col.
Anthropometric measurements
BMI was calculated as weight (in kilograms) divided by
height (in meters) squared.
Analytical determinations
The serum glucose levels were measured in duplicate by the
glucose oxidase method with a Beckman Glucose Analyzer
2 (Brea, CA). The coefficient of variation (CV) was 1.9%.
Total serum cholesterol was measured through the reaction
of cholesterol esterase/oxidase/peroxidase, using a BM/
Hitachi 747. HDL cholesterol was quantified after precipi-
tation with polyethylene glycol at room temperature. Total
serum triglycerides were measured through the reaction of
glycerol-phosphate-oxidase and peroxidase by routine labo-
ratory tests. HbA1c was measured by the high-performance
liquid chromatography method (Bio-Rad, Muenchen, Ger-
many). Intraassay and interassay coefficients of variation
was less than 4%.
Isolation of adipose tissue fractions
In a subsample of these subjects, we performed the isola-
tion of adipocyte and stromo-vascular fraction (SVF). Tis-
sues were washed three to four times with phosphate-
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PBS supplemented with 1% bovine serum and 0.1% colla-
genase type I (fabricant) prewarmed to 37°C. The tissue
was placed in a shaking water bath at 37°C with continuous
agitation for 60 minutes and centrifuged for 5 minutes at
300 to 500 g at room temperature. The supernatant, contain-
ing mature adipocytes, was recollected. The pellet was
identified as the SVF. The adipose tissue fractionation was
performed from 10 visceral and 8 subcutaneous fat depots.
Cell culture
Commercially available cryo-preserved human subcutane-
ous pre-adipocytes from two non-diabetic male subjects
with age>40 and Body Mass Index (BMI) <25 or BMI>30
Kg/m2 (SP-F-1 or SP-F-3, respectively; Zen-Bio, Inc.) were
plated on T-75 cell culture flasks and cultured at 37°C and
5% CO2 in Dulbecco's modified Eagle's medium (DMEM)/
Nutrient Mix F-12 medium (1:1, v/v) supplemented with
Fetal Bovine Serum (FBS) 10%, HEPES 1%, Glutamine
1% and Penicillin/Streptomycin (P/S) at 10 U/mL (all from
GIBCO, BRL; Grand Island, NY). One week later, human
subcutaneous pre-adipocytes were resuspended and cul-
tured (~40.000 cells/cm2, 3rd passage) in 12- or 96-well
plates with Pre-adipocyte Medium (PM; Zen-Bio, Inc.)
composed of DMEM/Nutrient Mix F-12 medium (1:1, v/v),
FBS 10%, HEPES 1%, Glutamine 1% and P/S 1% in a
humidified 37°C incubator with 5% CO2. Twenty-four
hours after plating, cells were checked for complete conflu-
ence (day 0) and differentiation was induced using Differ-
entiation Medium (DM; Zen-Bio, Inc.), composed of PM
with human Insulin (Ins), Dexamethasone (DXM), Isobu-
tylmethyl-xanthine (IBMX) and PPARγ agonists (Rosiglita-
zone, Rs). After 7 days (day 7), DM was replaced with
fresh Adipocyte Medium (AM; Zen-Bio Inc.), composed of
DMEM/Nutrient Mix F-12 medium (1:1, v/v), FBS,
HEPES, Biotin, Panthothenate, human Insulin (Ins), Dex-
amethasone (DXM), Penicillin, Streptomycin and Amphot-
ericin, according to manufacturers' guidelines. Two weeks
after the initiation of differentiation (day 14), cells appeared
rounded with large lipid droplets apparent in the cytoplasm.
Cells were then considered mature adipocytes (MAs), har-
vested and stored at -80°C for RNA extraction to study
gene expression levels, or fixed and immunostained (96-
well plates). For gene expression analyses, three biological
replicates (n = 3) of fat cells from both lean and obese sub-
jects were performed.
Gene expression analyses
RNA was prepared from adipose tissue fragments using
RNeasy Lipid Tissue Mini Kit (QIAgen, US). The integrity
of each RNA sample was checked by either agarose gel
electrophoresis or with an Agilent Bioanalyzer® (Agilent
Technologies, Palo Alto, CA). Total RNA was quantified by
means of spectrophotometer (GeneQuant, GE Health Care,
Piscataway NJ) or with the bioanalyzer. 3 ug of RNA from
each fat sample were then reverse transcribed to cDNA
using High Capacity cDNA® Archive Kit (Applied Biosys-
tems, Darmstadt, Germany) according to the manufacturer's
protocol.
Gene expression was assessed by real time PCR using an
ABI Prism®  7000 Sequence Detection System (Applied
Biosystems, Darmstadt, Germany), using TaqMan® tech-
nology suitable for relative gene expression quantification.
The reaction was performed following manufacturers' pro-
tocol in a final volume of 25 μl. The cycle program con-
sisted of an initial denaturing of 10 min at 95°C then 40
cycles of 15 sec denaturizing phase at 92°C and 1 min
annealing and extension phase at 60°C. Positive and nega-
tive controls were included in all the reactions.
The SybrGreen® primer sets used were previously vali-
dated to give an optimal amplification over serial dilutions
of target, and analysis of melting curves demonstrated spe-
cific single product for each gene primer. Primer sequences
were as follows: PPIA forward/reverse primer sequences
were 5'-CAAATGCTGGACCCAACACAA/CCTCCA-
CAATATTCATGCCTTCTT-3' respectively; CAV-1  for-
ward/reverse primer sequences were 5'-
AACGATGACGTGGTCAAGATTG-3' and 5'-TCCAAAT-
GCCGTCAAAACTGT-3', respectively.
The commercially available and pre-validated TaqMan®
primer/probe sets used were as follows: Cyclophilin A
(PPIA; Hs99999904_m1, RefSeq. NM_002046.3) was used
such as endogenous control for all target genes in each reac-
tion and Spot 14 homolog rat (THRSP; Hs009300 58_m1,
RefSeq. NM_003251.2), Fatty Acid Synthase (FASN;
Hs00188012_m1, RefSeq. NM_004104.4), Acetyl-Coen-
zyme A Carboxylase alpha (ACACA; Hs00167385_m1,
RefSeqs. NM_198834.1, NM_198836.1, NM_19883 7.1,
NM_198838.1 and NM_198839.1) and Sterol regulatory
element binding protein 1 (SREBP1; Hs00231674_m1, Ref-
Seq. NM_004104.4) were the target genes.
In both RT-PCR techniques, SybrGreen® and TaqMan®, a
threshold cycle (Ct value) was obtained for each amplifica-
tion curve and a ΔCt value was first calculated by subtract-
ing the Ct value for human Cyclophilin A (PPIA) cDNA
from the Ct value for each sample and transcript. Fold
changes compared with the endogenous control were then
determined by calculating 2-ΔCt, so gene expression results
are expressed in all cases as expression ratio relative to
PPIA gene expression according to manufacturers' instruc-
tions.
Western blot
Tissues were homogenized and protein content was mea-
sured as follows. Equal amounts of protein (25 μg) were run
out in 12% SDS-PAGE, subsequently transferred to nitro-
cellulose membranes (Bio-Rad Laboratories, Inc., Hercu-
les, CA) and blocked in Tris-buffered saline (10 mmol/L
Tris-HCl, 150 mmol/L NaCl, pH 8.0) with 0.05% Tween 20
(TBS-T) containing 5% non-fat dry milk for 1 h at roomFernández-Real et al. Nutrition & Metabolism 2010, 7:20
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temperature (RT). Blots were then incubated overnight at 4
°C with a rabbit polyclonal anti-CAV1 antibody (C 4490,
Sigma, St Louis, MO) or murine monoclonal anti-β-actin
(A 5441, Sigma). The antigen-antibody complexes were
visualized using horseradish peroxidase-conjugated anti-
rabbit or anti-mouse IgG antibodies (1:5,000) and the
enhanced chemiluminescence ECL detection system
(Amersham Biosciences, Buckinghamshire, UK). The
intensity of the bands was determined by densitometric
analysis with the Gel Doc™ gel documentation system and
Quantity One 4.5.0 software (Bio-Rad) and normalized
with  β-actin densitometric values. All assays were per-
formed in duplicate.
Statistical analyses
Descriptive results of continuous variables are expressed as
mean ± SD. Before statistical analysis, normal distribution
and homogeneity of the variances were evaluated using
Levene's  test. Paired and unpaired t-tests, or one-way
ANOVA for multiple comparisons, using post-hoc by Bon-
ferroni's test when equal variances could be assumed, was
used to compare groups with respect to continuous vari-
ables. Relation between quantitative variables was tested
using Pearson's test. All data were expressed as means ±
SD. The statistical analyses and graphics were performed
using the program SPSS (version 13.0).
Results
The anthropometric and metabolic variables of the studied
subjects and the gene expression levels for CAV-1, FAS, ste-
rol-regulatory-element-binding protein-1c (SREBP-1c) and
Spot-14  from both men and women are summarized in
Table 1. Of the studied subjects, 55 had normal fasting glu-
cose, 23 impaired fasting glucose and 12 type 2 diabetes.
Obese subjects showed decreased expression of CAV-1 in
visceral but not in subcutaneous adipose tissue (Table 1 and
Figure 1). These results were confirmed at the protein level
(Figure 2).
Associations of CAV-1 expression with lipogenic genes
In all subjects as a whole, CAV-1 gene expression in vis-
ceral adipose tissue (v-CAV-1) was positively associated
with the lipogenic genes acetyl-coA carboxylase (ACACA, r
= 0.34, p = 0.004), Spot-14 (r = 0.33, p = 0.004), PPAR-γ
co-activator-1 (PGC-1) (r = 0.57, p = 0.003, n = 24) and
tended to be associated with FAS gene expression (r = 0.21,
p = 0.07). v-CAV-1 was not associated with SREBP-1c gene
expression (r = -0.08, p = 0.4). However, these associations
were mainly due to the observations in non-obese subjects,
in whom v-CAV-1 correlated with FAS (r = 0.60, p < 0.0001,
Figure 3A), Spot-14 (r = 0.35, p = 0.006) and PGC-1 (r =
0.93, p = 0.002, n = 7) gene expressions. All these associa-
tions were not significant in obese subjects. Fasting triglyc-
erides correlated weakly with v-CAV-1  (r = -0.26, p =
0.049).
Divergent results were observed regarding CAV-1 gene
expression in subcutaneous adipose tissue (sc-CAV-1),
which was only associated with PGC-1 gene expression (r =
0.47, p = 0.009, n = 30) when obese and non-obese subjects
were studied together. In obese subjects, sc-CAV-1  was
associated with FAS  gene expression (r = 0.36, p = 0.02),
ACACA  (r = 0.33, p = 0.03), SREBP-1c  (r = 0.58, p <
0.0001), spot-14 (r = 0.36, p = 0.02), PGC-1 (r = 0.88, p =
0.001, n = 19). None of these associations was significant in
non-obese subjects.
Associations with metabolic variables
Fasting glucose or glycated hemoglobin were not signifi-
cantly associated with v-CAV-1 or sc-CAV-1. However, in
non-obese subjects with normal fasting glucose, sc-CAV-1
was negatively associated with glycated hemoglobin (r = -
0.58, p = 0.004, n = 12).
In obese subjects, sc-CAV-1  was associated negatively
with fasting triglycerides (r = -0.50, p < 0.0001, Figure 3B).
Multiple linear regression analyses disclosed that age (p =
0.027), fasting glucose (p = 0.002) and sc-CAV-1  gene
expression (p = 0.002) contributed to 8%, 12% and 20%,
respectively, of fasting triglycerides variance after adjusting
for BMI and sex.
Figure 1 Gene expression levels for visceral-CAV-1. Mean and 95% 
confidence interval for the mean of CAV-1 levels in visceral adipose tis-
sue from non-obese (BMI<30 kg/m2), obese (30 ≤ BMI<40 kg/m2) and 
morbidly obese subjects (BMI ≥ 40 kg/m2). The differences between 
obese and non-obese groups were highly significant (p < 0.0001).
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Study of CAV-1 expression in tissue fractions and during 
differentiation of preadipocytes
In both subcutaneous and visceral fat depots, CAV-1 expres-
sion in mature adipocytes was significantly higher than in
SVF (Figure 4A and 4B). In the visceral but not in the sub-
cutaneous fat depot, CAV-1 expression in adipocytes was
significantly higher than in SVF (1.56 ± 0.47 vs. 0.36 ±
0.19, p < 0.0001, Figure 4C and 4D). CAV-1 gene expres-
sion in adipocytes from subcutaneous adipose tissue (but
not in adipocytes from visceral adipose tissue) was signifi-
cantly associated with fasting triglycerides (r = -0.95, p <
0.0001). Conversely, CAV-1  expression in SVF from vis-
ceral adipose tissue was negatively associated with fasting
glucose (r = -0.77, p = 0.01), glycated hemoglobin (r = -
0.87, p = 0.01) and fasting triglycerides (r = -0.81, p =
0.01).
Finally, CAV-1 gene expression did not change signifi-
cantly during differentiation of human preadipocytes from
lean or obese subjects (Figure 4D and 4E) despite signifi-
cant increase of FAS gene expression.
Discussion
The main findings of this manuscript are: 1) CAV-1 gene
expression was significantly decreased in visceral adipose
tissue of obese subjects (Figure 1); in fact, this is the first
large study evaluating the expression of CAV-1 in adipose
tissue. CAV-1 gene expression has been previously reported
in a sample of 15 subjects [12]. 2) CAV-1 gene expression
in whole adipose tissue was significantly associated with
the expression of lipogenic genes and fasting triglycerides;
3) CAV-1 gene expression was significantly increased in
mature adipocytes compared with SVC fraction from both
visceral and subcutaneous adipose tissue (Figure 3A and
3B); 4) the expression of CAV-1 was significantly decreased
in mature adipocytes from the visceral fat compartment;
and 5) CAV-1 gene expression did not change significantly
during differentiation of human preadipocytes from lean or
obese subjects.
The type of fat depot (subcutaneous vs. visceral) and obe-
sity status significantly influenced these associations. In
non-obese subjects, with a wide range of CAV-1 in visceral
adipose tissue (v-CAV-1), significant and positive associa-
tions of v-CAV-1  with the main lipogenic genes were
observed. Decreased expression of v-CAV-1 of obese sub-
jects, with a relatively low range of v-CAV-1, could have
led to the absence of relationship with lipogenic genes in
this obese group. CAV-1 gene expression is known to be
controlled by sterol-regulatory-element-binding protein
(SREBP) [4], one of the main transcriptional factors
involved in lipogenesis, so these findings should be inter-
preted in this context.
Fasting triglycerides were not linked to v-CAV-1 in obese
and non-obese subjects. sc-CAV-1, however, was associated
with lipogenic genes (FAS, ACACA, SREBP-1c, PGC-1 and
Spot-14 [13]) and fasting triglycerides only in obese sub-
jects. Those obese subjects with decreased sc-CAV-1 had
the highest fasting triglyceride concentrations, paralleling,
to some extent, the observations of hypertriglyceridemia in
CAV-1 knockout mice [8]. The question remains why only
decreased sc-CAV-1 and not decreased v-CAV-1 was linked
to increased triglycerides. In fact, we found that CAV-1
gene expression in adipocytes was significantly higher than
in SVF in both subcutaneous and visceral fat depots. Even
though, when we compared adipocyte fractions, only CAV-
1 expression in subcutaneous adipose tissue was negatively
associated with fasting triglycerides. In this sense, the pro-
tective "metabolic" role of subcutaneous adipose tissue is
increasingly recognized [14]. CAV-1 expression in subcuta-
neous adipose tissue could be the reflection of a protective
role of CAV-1 in the metabolism of triglycerides.
CAV-1 gene expression did not change significantly dur-
ing differentiation of human pre-adipocytes despite a sig-
Figure 2 Western blot. Protein validation showing decreased CAV-1 
protein levels in obese subjects, and the 95% confidence interval for 
the mean of relative CAV-1 levels in non-obese and obese subjects 
(lower panel).
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nificant increase of FAS gene expression, a marker of
adipocyte differentiation. This is in contrast to what has
been observed in 3T3-L1 cells, in which CAV-1 gene
expression increases during differentiation [15-17]. This
finding suggests that CAV-1 is not under the control of adi-
pogenic factors in human adipocytes but influenced by
other components located in the microenvironment of the
adipose tissue. For instance, CAV-1 gene expression has
been detected in macrophages under the influence of
lipopolysaccharide [18,19], a bacterial product known to be
increased in human obesity [20,21]. However, we cannot
exclude that human pre-adipocytes have already entered
into senescence. In fact, increased caveolin-1 has been
described as a cause for the declined adipogenic potential of
senescent human mesenchymal stem cells[22].
On the other hand, the inverse association between CAV-1
gene expression and fasting glucose, glycated hemoglobin
and fasting triglycerides in SVC from visceral fat could
reflect the differential metabolic activity of the visceral fat
depot.
Decreased expression of v-CAV-1 is in contrast with pre-
vious findings in women, in whom both v-CAV-1 and sc-
Table 1: Anthropometric and biochemical characteristics of studied subjects.
Non-obese Obese Morbidly Obese p
N 39 17 34
Sex (M/F) 15/24 6/11 10/24 0.72
Body Mass Index (kg/m2) 25.4 ± 3.5 35.3 ± 3.1 46.1 ± 5.5 < 0.0001
Age (years) 46.7 ± 13.7 53.1 ± 14.9 43.1 ± 11 0.03
Glucose (mg/dl) 93.8 ± 32.2 91.25 ± 11.8 124.8 ± 59.4 0.005
Cholesterol (mg/dl) 195.5 ± 41.5 182.2 ± 34.8 189 ± 31.6 0.47
LDL-cholesterol (mg/
dl)
118 ± 35.8 99.6 ± 32.1 110.8 ± 36.7 0.27
HDL-cholesterol (mg/
dl)
57.2 ± 16.7 54.5 ± 16.9 59.15 ± 58.7 0.93
Log fasting 
tryglicerides
1.98 ± 0.2 2.03 ± 0.2 2.11 ± 0.2 0.08
ACACA visceral (RU) 0.04 ± 0.01 0.017 ± 0.003 0.02 ± 0.001 0.001
ACACA 
subcutaneous (RU)*
0.033 ± 0.006 0.015 ± 0.002 0.02 ± 0.002 0.03
FASN visceral (RU) 0.16 ± 0.02 0.07 ± 0.01 0.09 ± 0.01 0.02
FASN subcutaneous 
(RU)*
0.36 ± 0.14 0.07 ± 0.02 0.06 ± 0.009 0.01
SREBP-1c visceral 
(RU)
0.018 ± 0.002 0.013 ± 0.001 0.014 ± 0.001 0.2
SREBP-1c 
subcutaneous (RU)*
0.019 ± 0.004 0.009 ± 0.001 0.009 ± 0.001 0.04
Spot-14 visceral (RU) 0.26 ± 0.03 0.26 ± 0.03 0.23 ± 0.01 0.6
Spot-14 
subcutaneous (RU)*
0.60 ± 0.05 0.45 ± 0.003 0.48 ± 0.03 0.04
Caveolin visceral (RU) 1.68 ± 0.9 1.04 ± 0.3 1.05 ± 0.3 < 0.0001
Caveolin 
subcutaneous (RU)*
1.50 ± 0.4 1.78 ± 0.8 1.44 ± 0.4 0.22
ACACA, acetyl coA carboxylase; FAS, fatty acid synthase; SREBP-1c, sterol-regulatory-element-binding protein; RU, relative units. Values are 
expressed as mean ± SD except for gene expressions that are expressed as mean ± SEM.
*Subcutaneous adipose samples were studied in 16 non-obese, 13 obese and 26 morbidly obese subjects.Fernández-Real et al. Nutrition & Metabolism 2010, 7:20
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CAV-1 were increased among obese women [12]. However,
this latter study was performed in young women. Estrogen
receptors have been reported to associate with and regulate
the production of CAV-1 [23,24]. It is thus possible that the
confounding effects of estrogens in pre-menopausal women
could have played a role in these discrepant results.
A remarkable reduction in the expression of the genes
controlling lipogenic enzymes, namely SREBP-1c, and
genes coding lipogenic enzymes (FAS, phosphoenol pyru-
vate carboxykinase (PEPCK), ATP citrate-lyase, pyruvate
carboxylase) [25-27] has been demonstrated in obesity, a
situation in which hypertriglyceridemia is frequently pres-
ent despite that triglyceride synthesis and lipogenic genes
are positively correlated. In CAV-1 null mice the impaired
triglyceride clearance took place in the setting of normal
total and hepatic lipoprotein lipase activity, and reduced
hepatic very low-density lipoprotein (VLDL) secretion[9].
Conclusions
Caveolins are integral membrane proteins that serve as
scaffolds to recruit numerous signaling molecules, impli-
cated in membrane traffic, signal transduction, substrate
transport and endocytosis. The finding of decreased CAV-1
gene expression in adipocytes from obese subjects, and the
associations with lipogenic genes and triglycerides will
help to understand the alterations of intracellular signaling
and lipid synthesis in obesity. The regulation of CAV-1 gene
expression seems independent of the adipogenic program.
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